glucagon · Amphastar Pharms Inc · NDA 210134
Baqsimi
Earliest generic entry, as listed
23 Sep 2039
Blocked by patent: US 10765602.
Listed patents · 3 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 10765602 | product | 23 Sep 2039 |
| US 10213487 | product, use U-2604 | 16 Feb 2036 |
| US 12370241 | product, use U-2604 | 16 Feb 2036 |
Exclusivities · 1 unexpired
| NPP | new patient population | 17 Mar 2028 |
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 210134 · 001 · RLD | powder, nasal | 3MG | 23 Sep 2039 |